Annual EBITDA
-$176.58 M
-$4.35 M-2.52%
December 31, 2024
Summary
- As of March 10, 2025, FATE annual EBITDA is -$176.58 million, with the most recent change of -$4.35 million (-2.52%) on December 31, 2024.
- During the last 3 years, FATE annual EBITDA has risen by +$34.57 million (+16.37%).
- FATE annual EBITDA is now -1298.30% below its all-time high of -$12.63 million, reached on December 31, 2011.
Performance
FATE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$42.20 M
+$5.57 M+11.66%
December 31, 2024
Summary
- As of March 10, 2025, FATE quarterly EBITDA is -$42.20 million, with the most recent change of +$5.57 million (+11.66%) on December 31, 2024.
- Over the past year, FATE quarterly EBITDA has increased by +$5.57 million (+11.66%).
- FATE quarterly EBITDA is now -1182.22% below its all-time high of -$3.29 million, reached on March 31, 2013.
Performance
FATE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$176.58 M
+$992.00 K+0.56%
December 31, 2024
Summary
- As of March 10, 2025, FATE TTM EBITDA is -$176.58 million, with the most recent change of +$992.00 thousand (+0.56%) on December 31, 2024.
- Over the past year, FATE TTM EBITDA has increased by +$992.00 thousand (+0.56%).
- FATE TTM EBITDA is now -4949.39% below its all-time high of -$3.50 million, reached on September 30, 2012.
Performance
FATE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
FATE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.5% | +11.7% | +0.6% |
| 3 y3 years | +16.4% | +11.7% | +0.6% |
| 5 y5 years | -87.4% | +11.7% | +0.6% |
FATE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2.5% | +40.1% | -72.9% | +49.3% | -2.5% | +41.6% |
| 5 y | 5-year | -87.4% | +40.1% | -72.9% | +49.3% | -87.4% | +41.6% |
| alltime | all time | -1298.3% | +40.1% | -1182.2% | +49.3% | -4949.4% | +41.6% |
Fate Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$176.58 M(+2.5%) | -$42.20 M(-11.7%) | -$176.58 M(-0.6%) |
| Sep 2024 | - | -$47.77 M(+18.4%) | -$177.57 M(+0.7%) |
| Jun 2024 | - | -$40.36 M(-12.7%) | -$176.34 M(-9.1%) |
| Mar 2024 | - | -$46.25 M(+7.1%) | -$194.07 M(+12.7%) |
| Dec 2023 | -$172.23 M(-41.5%) | -$43.19 M(-7.2%) | -$172.23 M(-8.7%) |
| Sep 2023 | - | -$46.54 M(-19.9%) | -$188.62 M(-16.3%) |
| Jun 2023 | - | -$58.10 M(+138.1%) | -$225.28 M(-8.9%) |
| Mar 2023 | - | -$24.40 M(-59.0%) | -$247.32 M(-16.1%) |
| Dec 2022 | -$294.63 M(+39.5%) | -$59.58 M(-28.4%) | -$294.63 M(-2.5%) |
| Sep 2022 | - | -$83.20 M(+3.8%) | -$302.23 M(+11.1%) |
| Jun 2022 | - | -$80.15 M(+11.8%) | -$272.13 M(+14.5%) |
| Mar 2022 | - | -$71.71 M(+6.7%) | -$237.60 M(+12.5%) |
| Dec 2021 | -$211.14 M(+68.9%) | -$67.18 M(+26.5%) | -$211.14 M(+19.6%) |
| Sep 2021 | - | -$53.10 M(+16.4%) | -$176.51 M(+14.5%) |
| Jun 2021 | - | -$45.61 M(+0.8%) | -$154.12 M(+12.9%) |
| Mar 2021 | - | -$45.25 M(+39.1%) | -$136.46 M(+9.2%) |
| Dec 2020 | -$125.00 M(+32.7%) | -$32.54 M(+5.9%) | -$125.00 M(+4.5%) |
| Sep 2020 | - | -$30.71 M(+9.9%) | -$119.60 M(+4.4%) |
| Jun 2020 | - | -$27.96 M(-17.2%) | -$114.51 M(+5.0%) |
| Mar 2020 | - | -$33.79 M(+24.5%) | -$109.08 M(+15.8%) |
| Dec 2019 | -$94.20 M(+47.9%) | -$27.14 M(+5.9%) | -$94.20 M(+14.4%) |
| Sep 2019 | - | -$25.62 M(+13.7%) | -$82.33 M(+13.2%) |
| Jun 2019 | - | -$22.53 M(+19.1%) | -$72.75 M(+5.2%) |
| Mar 2019 | - | -$18.91 M(+23.9%) | -$69.18 M(+8.6%) |
| Dec 2018 | -$63.70 M | -$15.27 M(-4.8%) | -$63.70 M(+5.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$16.04 M(-15.3%) | -$60.22 M(+11.0%) |
| Jun 2018 | - | -$18.95 M(+41.0%) | -$54.24 M(+21.9%) |
| Mar 2018 | - | -$13.44 M(+13.9%) | -$44.50 M(+9.3%) |
| Dec 2017 | -$40.71 M(+31.6%) | -$11.79 M(+17.2%) | -$40.71 M(+12.1%) |
| Sep 2017 | - | -$10.06 M(+9.3%) | -$36.33 M(+5.6%) |
| Jun 2017 | - | -$9.20 M(-4.7%) | -$34.40 M(+4.4%) |
| Mar 2017 | - | -$9.65 M(+30.3%) | -$32.94 M(+6.4%) |
| Dec 2016 | -$30.94 M(+14.2%) | -$7.41 M(-8.9%) | -$30.94 M(+2.3%) |
| Sep 2016 | - | -$8.13 M(+5.1%) | -$30.23 M(+7.1%) |
| Jun 2016 | - | -$7.74 M(+1.0%) | -$28.24 M(+2.5%) |
| Mar 2016 | - | -$7.66 M(+14.4%) | -$27.55 M(+1.7%) |
| Dec 2015 | -$27.09 M(+9.0%) | -$6.70 M(+9.2%) | -$27.09 M(+3.4%) |
| Sep 2015 | - | -$6.14 M(-13.0%) | -$26.20 M(-0.6%) |
| Jun 2015 | - | -$7.05 M(-2.0%) | -$26.37 M(+4.6%) |
| Mar 2015 | - | -$7.20 M(+23.7%) | -$25.22 M(+1.5%) |
| Dec 2014 | -$24.84 M(+27.2%) | -$5.82 M(-7.7%) | -$24.84 M(+2.4%) |
| Sep 2014 | - | -$6.30 M(+6.7%) | -$24.25 M(+2.5%) |
| Jun 2014 | - | -$5.91 M(-13.3%) | -$23.66 M(+2.6%) |
| Mar 2014 | - | -$6.81 M(+30.2%) | -$23.05 M(+18.0%) |
| Dec 2013 | -$19.53 M(+48.4%) | -$5.23 M(-8.3%) | -$19.53 M(+6.3%) |
| Sep 2013 | - | -$5.70 M(+7.6%) | -$18.37 M(+13.6%) |
| Jun 2013 | - | -$5.30 M(+61.1%) | -$16.17 M(+48.8%) |
| Mar 2013 | - | -$3.29 M(-19.3%) | -$10.87 M(+43.4%) |
| Dec 2012 | -$13.16 M(+4.2%) | -$4.08 M(+16.6%) | -$7.58 M(+116.6%) |
| Sep 2012 | - | -$3.50 M | -$3.50 M |
| Dec 2011 | -$12.63 M | - | - |
FAQ
- What is Fate Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Fate Therapeutics?
- What is Fate Therapeutics annual EBITDA year-on-year change?
- What is Fate Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Fate Therapeutics?
- What is Fate Therapeutics quarterly EBITDA year-on-year change?
- What is Fate Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Fate Therapeutics?
- What is Fate Therapeutics TTM EBITDA year-on-year change?
What is Fate Therapeutics annual EBITDA?
The current annual EBITDA of FATE is -$176.58 M
What is the all time high annual EBITDA for Fate Therapeutics?
Fate Therapeutics all-time high annual EBITDA is -$12.63 M
What is Fate Therapeutics annual EBITDA year-on-year change?
Over the past year, FATE annual EBITDA has changed by -$4.35 M (-2.52%)
What is Fate Therapeutics quarterly EBITDA?
The current quarterly EBITDA of FATE is -$42.20 M
What is the all time high quarterly EBITDA for Fate Therapeutics?
Fate Therapeutics all-time high quarterly EBITDA is -$3.29 M
What is Fate Therapeutics quarterly EBITDA year-on-year change?
Over the past year, FATE quarterly EBITDA has changed by +$5.57 M (+11.66%)
What is Fate Therapeutics TTM EBITDA?
The current TTM EBITDA of FATE is -$176.58 M
What is the all time high TTM EBITDA for Fate Therapeutics?
Fate Therapeutics all-time high TTM EBITDA is -$3.50 M
What is Fate Therapeutics TTM EBITDA year-on-year change?
Over the past year, FATE TTM EBITDA has changed by +$992.00 K (+0.56%)